Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shandong Boan Biotechnology Co's enterprise value is €199.09 Mil.
Shandong Boan Biotechnology Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.34 Mil. Therefore, Shandong Boan Biotechnology Co's EV-to-EBITDA for today is -148.13.
The historical rank and industry rank for Shandong Boan Biotechnology Co's EV-to-EBITDA or its related term are showing as below:
FRA:UJ9'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -263.33 Med: -27.38 Max: 54.39
Current: -156.37
During the past 6 years, the highest EV-to-EBITDA of Shandong Boan Biotechnology Co was 54.39. The lowest was -263.33. And the median was -27.38.
FRA:UJ9's EV-to-EBITDA is ranked worse than 100% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs FRA:UJ9: -156.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shandong Boan Biotechnology Co (FRA:UJ9) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shandong Boan Biotechnology Co's PE Ratio (TTM) for today is calculated as:
Shandong Boan Biotechnology Co's share price for today is €0.37.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shandong Boan Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UJ9 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's EV-to-EBITDA falls into.
Shandong Boan Biotechnology Co's current Enterprise Value is €199.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shandong Boan Biotechnology Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co (FRA:UJ9) has a EV-to-EBITDA of -148.13 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shandong Boan Biotechnology Co. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #999999 out of 399 companies in the Biotechnology industry.
Is Shandong Boan Biotechnology Co's EV-to-EBITDA too high?
Shandong Boan Biotechnology Co's current EV-to-EBITDA is -148.13. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #999999 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #999999 out of 399 companies for EV-to-EBITDA. This places Shandong Boan Biotechnology Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shandong Boan Biotechnology Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Boan Biotechnology Co's current EV-to-EBITDA is -148.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current EV-to-EBITDA of -148.13. The stock's GF Value™ is €1.80, compared to a current price of €0.37 — trading 79.4% below its estimated fair value. The current EV-to-EBITDA is -148.13. Shandong Boan Biotechnology Co's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current EV-to-EBITDA is -148.13 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.37 is trading 79.4% below its estimated GF Value™ of €1.80.
Key valuation signals for FRA:UJ9:
EV-to-EBITDA: -148.13
GF Value™: €1.80 vs. price of €0.37 (79.4% below fair value)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
42GF Score
Get the complete analysis for FRA:UJ9
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
